Similar articles

Abstract: Objective: percutaneous coronary intervention (PCI) triggers an acute inflammatory response, while sirolimus is known to have anti-inflammatory properties; the inflammatory system response to PCI after sirolimus-eluting stent placement remains unclear. The purpose of this study is to determine the changes in high sensitive C-reactive protein (hs-CRP) and apelin after PCI procedure and drug-eluting stent implantation in patients with and without reduced left ventricular systolic function. Methods: Forty-eight consecutive patients undergoing PCI at the Beijing Anzhen Hospital between July and September 2006 were recruited. Sirolimus-eluting stents were employed in all patients. Blood samples were drawn immediately before and 24 h after the procedure. Plasma hs-CRP and apelin levels were determined by enzyme immunoassay. Results: Paired t-test revealed a significant increase in both hs-CRP and apelin post-procedure (P=0.006 and P<0.0001, respectively). Patients with reduced left ventricular ejection fraction (LVEF) had significantly lower baseline apelin levels compared to those with normal ventricular function [(46.8±10.8) vs. (72.0±8.4) pg/ml, P<0.001]. However, apelin increased to a level similar to the level of those with normal left ventricular systolic function 24 h after the PCI procedure [(86.7±11.6) vs. (85.1±6.1) pg/ml, P=0.72]. Conclusions: hs-CRP and apelin levels increased after PCI and sirolimus-eluting stent implantation. Patients with impaired left ventricular systolic function had significantly lower baseline apelin levels, which increased significantly after PCI.

[1]Almagor, M., Keren, A., Banai, S., 2003. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. American Heart Journal, 145(2):248-253.

[2]Bavry, A.A., Kumbhani, D.J., Helton, T.J., Borek, P.P., Mood, G.R., Bhatt, D.L., 2006. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. The American Journal of Medicine, 119(12):1056-1061.

[3]Chen, M.M., Ashley, E.A., Deng, D.X., Tsalenko, A., Deng, A., Tabibiazar, R., Ben-Dor, A., Fenster, B., Yang, E., King, J.Y., et al., 2003. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation, 108(12):1432-1439.

[4]Ellinor, P.T., Low, A.F., MacRae, C.A., 2006. Reduced apelin levels in lone atrial fibrillation. European Heart Journal, 27(2):222-226.

[5]Gogo, P.B., Schneider, D.J., Watkins, M.W., Terrien, E.F., Sobel, B.E., Dauerman, H.L., 2005. Systemic inflammation after drug-eluting stent placement. Journal of Thrombosis and Thrombolysis, 19(2):87-92.

[6]Habata, Y., Fujii, R., Hosoya, M., Fukusumi, S., Kawamata, Y., Hinuma, S., Kitada, C., Nishizawa, N., Murosaki, S., Kurokawa, T., et al., 1999. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochimica et Biophysica Acta, 1452(1):25-35.

[7]Hofma, S.H., van der Giessen, W.J., van Dalen, B.M., Lemos, P.A., McFadden, E.P., Sianos, G., Ligthart, J.M., van Essen, D., de Feyter, P.J., Serruys, P.W., 2006. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. European Heart Journal, 27(2):166-170.

[8]Hosoya, M., Kawamata, Y., Fukusumi, S., Fujii, R., Habata, Y., Hinuma, S., Kitada, C., Honda, S., Kurokawa, T., Onda, H., et al., 2000. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. Journal of Biological Chemistry, 275(28):21061-21067.

[9]Katugampola, S.D., Maguire, J.J., Matthewson, S.R., Davenport, A.P., 2001. [(125)I]-(Pyr(1)) apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. British Journal of Pharmacology, 132(6):1255-1260.

[10]Kim, J.Y., Ko, Y.G., Shim, C.Y., Park, S., Hwang, K.C., Choi, D., Jang, Y., Hung, N., Shim, W.H., Cho, S.Y., 2005. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. The American Journal of Cardiology, 96(10):1384-1388.

[11]Kleinz, M.J., Davenport, A.P., 2004. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regulatory Peptides, 118(3):119-125.

[12]Kochiadakis, G.E., Marketou, M.E., Arfanakis, D.A., Sfiridaki, K., Skalidis, E.I., Igoumenidis, N.E., Hamilos, M.I., Kolyvaki, S., Chlouverakis, G., Kantidaki, E., et al., 2007. Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. Atherosclerosis, 194(2):433-438.

[13]Kornowski, R., Hong, M.K., Tio, F.O., Bramwell, O., Wu, H., Leon, M.B., 1998. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. Journal of the American College of Cardiology, 31(1):224-230.

[14]Masri, B., Morin, N., Cornu, M., Knibiehler, B., Audigier, Y., 2004. Apelin (65–77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. The FASEB Journal, 8(5):1909-1911.

[15]Oberhoff, M., Herdeg, C., Baumbach, A., Karsch, K.R., 2002. Stent-based antirestenotic coatings (sirolimus/paclitaxel). Catheterization and Cardiovascular Interventions, 55(3):404-408.

[16]Serry, R., Penny, W.F., 2005. Endothelial dysfunction after sirolimus-eluting stent placement. Journal of the American College of Cardiology, 46(2):237-238.

[17]Szokodi, I., Tavi, P., Foldes, G., Voutilainen-Myllyla, S., Ilves, M., Tokola, H., Piuhola, J., Rysä, J., Tóth, M., Ruskoaho, H., 2002. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circulation Research, 91(5):434-440.

[18]Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M.X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C., et al., 1998. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochemical and Biophysical Research Communications, 251(2):471-476.

[19]Togni, M., Windecker, S., Cocchia, R., Wenaweser, P., Cook, S., Billinger, M., Meier, B., Hess, O.M., 2005. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. Journal of the American College of Cardiology, 46(2):231-236.